Search research articles
Contact Us
Filters
Showing results (161-170 of 265) with videos related to
Page
of 27
Sort By:
The Journal of Investigative Dermatology
|
October 27, 2018
Immunoglobulin E-Selective Immunoadsorption Reduces Peripheral and Skin-Bound Immunoglobulin E and Modulates Cutaneous IL-13 Expression in Severe Atopic Dermatitis
Kristian Reich, Anna Hartjen, Jeremias Reich, et al.
Dermatology and Therapy
|
March 4, 2021
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study
Ulrich Mrowietz, A David Burden, Andreas Pinter, et al.
JAMA Dermatology
|
May 12, 2021
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials
Jonathan I Silverberg, Eric L Simpson, Andreas Wollenberg, et al.
The Lancet. Rheumatology
|
January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study
Kim Papp, Richard B Warren, Lawrence Green, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
June 7, 2018
What is psoriasis? - Perception and assessment of psoriasis among the German population
Rachel Sommer, Ulrich Mrowietz, Marc Alexander Radtke, et al.
The Journal of Investigative Dermatology
|
June 18, 2019
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study
Kenneth B Gordon, April W Armstrong, Peter Foley, et al.
Lancet (London, England)
|
December 26, 2016
An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Richard B Warren, Ulrich Mrowietz, Ralph von Kiedrowski, et al.
The Journal of Dermatology
|
June 21, 2023
Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations
Seong Jin Jo, Yu-Huei Huang, Tsen-Fang Tsai, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
June 7, 2018
Was ist Schuppenflechte? - Wahrnehmung und Bewertung der Psoriasis in der deutschen Bevölkerung
Rachel Sommer, Ulrich Mrowietz, Marc Alexander Radtke, et al.
Annals of the Rheumatic Diseases
|
January 25, 2019
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Stefan Schreiber, Jean-Frederic Colombel, Brian G Feagan, et al.
Page
of 27
Search research articles
Search
Showing results (161-170 of 265) with videos related to
Sort By:
Page
of 27
The Journal of Investigative Dermatology
|
October 27, 2018
Immunoglobulin E-Selective Immunoadsorption Reduces Peripheral and Skin-Bound Immunoglobulin E and Modulates Cutaneous IL-13 Expression in Severe Atopic Dermatitis
Kristian Reich, Anna Hartjen, Jeremias Reich, et al.
Dermatology and Therapy
|
March 4, 2021
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study
Ulrich Mrowietz, A David Burden, Andreas Pinter, et al.
JAMA Dermatology
|
May 12, 2021
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials
Jonathan I Silverberg, Eric L Simpson, Andreas Wollenberg, et al.
The Lancet. Rheumatology
|
January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study
Kim Papp, Richard B Warren, Lawrence Green, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
June 7, 2018
What is psoriasis? - Perception and assessment of psoriasis among the German population
Rachel Sommer, Ulrich Mrowietz, Marc Alexander Radtke, et al.
The Journal of Investigative Dermatology
|
June 18, 2019
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study
Kenneth B Gordon, April W Armstrong, Peter Foley, et al.
Lancet (London, England)
|
December 26, 2016
An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Richard B Warren, Ulrich Mrowietz, Ralph von Kiedrowski, et al.
The Journal of Dermatology
|
June 21, 2023
Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations
Seong Jin Jo, Yu-Huei Huang, Tsen-Fang Tsai, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
June 7, 2018
Was ist Schuppenflechte? - Wahrnehmung und Bewertung der Psoriasis in der deutschen Bevölkerung
Rachel Sommer, Ulrich Mrowietz, Marc Alexander Radtke, et al.
Annals of the Rheumatic Diseases
|
January 25, 2019
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Stefan Schreiber, Jean-Frederic Colombel, Brian G Feagan, et al.
Page
of 27